Viatris Inc. (NASDAQ:VTRS) saw its stock drop 3.6% following news that its late-stage trial for MR-139, a potential treatment ...

What Happened? Shares of medication company Viatris (NASDAQ:VTRS) fell 3.8% in the afternoon session after its experimental ...

To avoid tick bites, wear long-sleeved shirts and long pants, and tuck your pants into your socks to stop ticks from climbing ...

As summertime family activities are in full swing, simultaneously, so is tick season. And while most tick bites are harmless, ...

Viatris's said on Friday that the trial of an ointment for people with blepharitis didn't meet its primary endpoint.

The FDA accepted Aldeyra's resubmitted NDA for reproxalap after previous rejections due to efficacy concerns, despite no ...

The tool is designed to help with the application of mono-dose, dry eye eyedrop vials more easily and accurately.

Treatment with botulinum toxin A appears to improve tear production and stability and relieve symptoms in patients with dry ...

Nanoscope Therapeutics submitted the first modules of a biologics license application for MCO-010, an investigational gene ...

Background/aims Artificial intelligence (AI) in Ophthalmology has yet to be applied to real-time cataract surgery. This work explores a new AI tool, developed for phacoemulsification, and evaluates ...

GSK has been enjoying regulatory momentum in recent months as it works to bring its antibody-drug conjugate (ADC) Blenrep ...

The FDA has accepted for review the second resubmitted NDA for reproxalap for the treatment of the signs and symptoms of dry eye disease.